|drug1701||Intervention group CoronaCope Wiki||1.00|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
The purpose of this research is to see if Intravenous Immunoglobulin (IVIG) can help reduce respiratory complications (respiratory failure and need for a ventilator) caused by coronavirus disease 2019 (COVID-19). The principal investigator has successfully utilized IVIG for patients infected with the influenza virus. The investigator wants to find out if IVIG is equally effective in COVID-19 infection patients, and if IVIG will give the immune system some help to clear the infection naturally.
Description: Number of subjects requiring mechanical ventilation due to respiratory failureMeasure: Mechanical Ventilation Time: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days
Description: Number of days requiring oxygen therapyMeasure: Oxygen Therapy Time: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days
Description: Number of days in hospitalMeasure: Length of Stay Time: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports